Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ashby

Showing results (171-180 of 320) with videos related to

Pageof 32
Sort By:
Medical Review (2021)|March 22, 2024
Nanotechnology-based delivery systems to overcome drug resistance in cancerHarsh Patel, Jiaxin Li, Letao Bo, et al.
The European Journal of Neuroscience|July 20, 2005
Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in ratsZheng-Xiong Xi, Jeremy G Gilbert, Arlene C Pak, et al.
Neuropharmacology|April 28, 2009
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in ratsKrista Spiller, Zheng-Xiong Xi, Xia Li, et al.
Biochemical Pharmacology|January 24, 2020
The nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate/D-NO), increases survival by attenuating hyperoxia-compromised innate immunity in bacterial clearance in a mouse model of ventilator-associated pneumoniaAshwini Gore, Alex G Gauthier, Mosi Lin, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|March 29, 2022
N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory ResponseZeng-Hui Wei, Oluwabukola O Salami, Jagadish Koya, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 10, 2021
Therapeutic strategies to overcome taxane resistance in cancerTuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1987
Anti-idiotypic antibodies as probes of protein active sites: application to cholera toxin subunit BD S Ludwig, R A Finkelstein, A E Karu, et al.
Oncology Reports|May 7, 2019
The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review)Yun Liu, Hongmei Sun, Bolat Makabel, et al.
The International Journal of Neuropsychopharmacology|September 1, 2006
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functionsArlene C Pak, Charles R Ashby, Christian A Heidbreder, et al.
Cancers|September 6, 2018
Cariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in CancerNoor Hussein, Charles R Ashby, Haneen Amawi, et al.
Pageof 32

Showing results (171-180 of 320) with videos related to

Sort By:
Pageof 32
Medical Review (2021)|March 22, 2024
Nanotechnology-based delivery systems to overcome drug resistance in cancerHarsh Patel, Jiaxin Li, Letao Bo, et al.
The European Journal of Neuroscience|July 20, 2005
Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in ratsZheng-Xiong Xi, Jeremy G Gilbert, Arlene C Pak, et al.
Neuropharmacology|April 28, 2009
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in ratsKrista Spiller, Zheng-Xiong Xi, Xia Li, et al.
Biochemical Pharmacology|January 24, 2020
The nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate/D-NO), increases survival by attenuating hyperoxia-compromised innate immunity in bacterial clearance in a mouse model of ventilator-associated pneumoniaAshwini Gore, Alex G Gauthier, Mosi Lin, et al.
Reproductive Sciences (Thousand Oaks, Calif.)|March 29, 2022
N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory ResponseZeng-Hui Wei, Oluwabukola O Salami, Jagadish Koya, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 10, 2021
Therapeutic strategies to overcome taxane resistance in cancerTuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1987
Anti-idiotypic antibodies as probes of protein active sites: application to cholera toxin subunit BD S Ludwig, R A Finkelstein, A E Karu, et al.
Oncology Reports|May 7, 2019
The targeting of non‑coding RNAs by curcumin: Facts and hopes for cancer therapy (Review)Yun Liu, Hongmei Sun, Bolat Makabel, et al.
The International Journal of Neuropsychopharmacology|September 1, 2006
The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functionsArlene C Pak, Charles R Ashby, Christian A Heidbreder, et al.
Cancers|September 6, 2018
Cariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in CancerNoor Hussein, Charles R Ashby, Haneen Amawi, et al.
Pageof 32